| P50 | author | Brian Druker | Q373427 |
| | Bill H. Chang | Q55292616 |
| P2093 | author name string | Christopher A Eide | |
| | Jeffrey W Tyner | |
| | Daniel Bottomly | |
| | Shannon K McWeeney | |
| | Julia E Maxson | |
| | Marc M Loriaux | |
| | Samuel B Luty | |
| | Beth Wilmot | |
| | Cristina E Tognon | |
| | Monika A Davare | |
| P2860 | cites work | Discovery of tissue-specific exons using comprehensive human exon microarrays | Q21092870 |
| | Anaplastic lymphoma kinase: signalling in development and disease | Q24312329 |
| | Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 |
| | Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 |
| | Activating mutations in ALK provide a therapeutic target in neuroblastoma | Q27851452 |
| | EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 |
| | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | Q27851671 |
| | Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML | Q27852275 |
| | Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 |
| | Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death | Q28202067 |
| | Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q28250347 |
| | Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 |
| | A framework for oligonucleotide microarray preprocessing. | Q34149103 |
| | Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. | Q34938204 |
| | Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. | Q35166315 |
| | Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | Q35575978 |
| | Anaplastic lymphoma kinase in human cancer | Q37866541 |
| | RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. | Q38194730 |
| | Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target | Q38326252 |
| | Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. | Q39411416 |
| | A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster | Q41008377 |
| | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, | Q42710837 |
| | GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers | Q43262263 |
| | ALK fusion genes in children with atypical myeloproliferative leukemia | Q84127631 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2146-2150 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Therapeutically Targetable ALK Mutations in Leukemia | |
| P478 | volume | 75 | |